Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 52 Week Randomized, Double-Blind, Multicenter, Mechanistic Study With a 24 Week Open-Label Follow-Up to Evaluate the Effect of AVANDIA TM on Bone in Postmenopausal Women With Type 2 Diabetes Mellitus
Brief Summary: The purpose of this study is to determine the effects of rosiglitazone on the bone in postmenopausal women with type 2 diabetes mellitus


Options:
A: Arm Label: Arm 1 Treatment A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rosiglitazone | Arm Label: Arm 2 Treatment B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin | Intervention Type: DRUG; Name: Rosiglitazone; Assigned to Arm(s): Arm 1 Treatment A | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Arm 2 Treatment B
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Comparator: MK0431 100 mg q.d. (q.d. = once daily) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Comparator: Metformin 500 mg b.i.d. | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Comparator: Metformin 1000 mg b.i.d. | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: Comparator: MK0431 50 mg b.i.d. (b.i.d. = twice daily), Drug: Comparator: Metformin 500 mg b.i.d. | Arm Label: 5; Type: EXPERIMENTAL; Interventions: Drug: Comparator: MK0431 50 mg b.i.d. (b.i.d. = twice daily), Drug: Comparator: Metformin 1000 mg b.i.d. | Arm Label: 6; Type: PLACEBO_COMPARATOR; Interventions: Drug: Comparator: Placebo (Phase A)/Metformin (Phase B) | Arm Label: 7; Type: EXPERIMENTAL; Interventions: Drug: Comparator: Open-Label MK0431/Metformin 50/1000 mg b.i.d. | Intervention Type: DRUG; Name: Comparator: MK0431 50 mg b.i.d. (b.i.d. = twice daily); Assigned to Arm(s): 4, 5 | Intervention Type: DRUG; Name: Comparator: MK0431 100 mg q.d. (q.d. = once daily); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Comparator: Placebo (Phase A)/Metformin (Phase B); Assigned to Arm(s): 6 | Intervention Type: DRUG; Name: Comparator: Metformin 500 mg b.i.d.; Assigned to Arm(s): 2, 4 | Intervention Type: DRUG; Name: Comparator: Open-Label MK0431/Metformin 50/1000 mg b.i.d.; Assigned to Arm(s): 7 | Intervention Type: DRUG; Name: Comparator: Metformin 1000 mg b.i.d.; Assigned to Arm(s): 3, 5
C: Intervention Type: DRUG; Name: vildagliptin; Assigned to Arm(s): N/A
D: Arm Label: 1.5 mg LY2189265; Type: EXPERIMENTAL; Interventions: Drug: LY2189265, Drug: Metformin, Drug: Pioglitazone | Arm Label: 0.75 mg LY2189265; Type: EXPERIMENTAL; Interventions: Drug: LY2189265, Drug: Metformin, Drug: Pioglitazone | Arm Label: Exenatide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Exenatide, Drug: Metformin, Drug: Pioglitazone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: LY2189265, Drug: Placebo, Drug: Metformin, Drug: Pioglitazone | Intervention Type: DRUG; Name: LY2189265; Assigned to Arm(s): 0.75 mg LY2189265, 1.5 mg LY2189265, Placebo | Intervention Type: DRUG; Name: Exenatide; Assigned to Arm(s): Exenatide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): 0.75 mg LY2189265, 1.5 mg LY2189265, Exenatide, Placebo | Intervention Type: DRUG; Name: Pioglitazone; Assigned to Arm(s): 0.75 mg LY2189265, 1.5 mg LY2189265, Exenatide, Placebo

Answer: A